Amsterdam 2015
Menu
AIDSImpact.com
Conference Details
Authors
International Committee
Plenary Speakers
Presenting Speakers
Programme
Sessions
Scientific Committee
Acknowledgements
| Abstract #2390 - Martin Fishbein Memorial Plenary | ||||
|
Session: 1.3: Martin Fishbein Memorial Plenary (Plenary) on Tuesday @ 12.30-14.30 in C103 Chaired by Kees Rietmeijer, Barbara Hedge, Kevin Malotte Authors: Presenting Author: Prof Dolores Albarracin - University of Illinois, United States |
||||
| Additional Authors: | ||||
| Aim: Intervention programs simultaneously targeting multiple health domains have gained popularity in the management of HIV. In contrast to programs designed to target a single domain of behavior change (e.g., adherence to antiretrovirals or smoking cessation), multi-behavior programs seek changes in clusters of behaviors that pose risk factors for the same disease (e.g., adherence to antiretrovirals and alcohol drinking). In addition, some programs often include pharmacologic agents (e.g., nicotine patches, weight-loss medications, antidepressants) designed to synergize with the behavioral recommendations. The aim of this presentation is to discuss the role of pharmacological agents in the efficacy of multi-behavior interventions. | ||||
| Method / Issue: This meta-analysis reviewed research reports of interventions promoting multiple behavior domain change. The main outcome measure was indicator of overall change that combined behavioral and biomedical/clinical effects. These effects were analyzed as a function of types of pharmacological agents. | ||||
| Results / Comments: Taken together, programs that included behaviorally-focused pharmacologic agents produced significant changes in behavioral outcomes, but had no significant effect on clinical or overall outcomes above and beyond that of the behavioral programs. In contrast, programs that included clinically-focused pharmacologic agents yielded significant positive changes above and beyond that of the behavioral program alone on (a) behavioral outcomes, (b) clinical outcomes and (c) total outcomes. | ||||
| Discussion: These findings are discussed in light of biomedical agents that can be used to maximize the management of HIV. Future research directions will also be addressed. | ||||
| Go Back | ||||